Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).

@article{Taiwo2011EfficacyOA,
  title={Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262).},
  author={Babafemi Olapoju Taiwo and Lu Zheng and S{\'e}bastien Gallien and Roy M. Matining and Daniel R. Kuritzkes and Cara C Wilson and Baiba I. Berzins and Edward P. Acosta and Barbara Bastow and Peter Sungwhan Kim and Joseph J Eron},
  journal={AIDS},
  year={2011},
  volume={25 17},
  pages={
          2113-22
        }
}
OBJECTIVE To explore darunavir/ritonavir (DRV/r) plus raltegravir (RAL) combination therapy in antiretroviral-naive patients. DESIGN Phase IIb, single-arm, open-label, multicenter study. METHODS One hundred and twelve antiretroviral-naive, HIV-1-infected patients received DRV/r 800/100 mg once daily and RAL 400 mg twice daily. Primary endpoint was virologic failure by week 24. Virologic failure was defined as confirmed viral load of 1000 copies/ml or more at week 12, or an increase of more… CONTINUE READING
Highly Cited
This paper has 42 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 20 citations